表紙
市場調查報告書
商品編碼
1083085

BRAF激酶抑制劑的全球市場:2022年∼2026年

Global BRAF Kinase Inhibitors Market 2022-2026

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球BRAF激酶抑制劑的市場規模在2022年∼2026年間,預測將成長到11億9,000萬美元,在預測期間內預計將以年複合成長率7.73%成長。

市場成長的主要因素有BRAF激酶抑制劑的高靶點親和力和特異性、患者支持計劃的存在以及癌症患病率增加等。

本報告提供全球BRAF激酶抑制劑市場相關調查分析,網羅市場規模與預測,趨勢,促進因素,課題,再加上約25家供應商的供應商分析等。

目錄

第1章 摘要整理

  • 市場概要

第2章 市場形勢

  • 市場生態系統

第3章 市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模:2021年
  • 市場預測:2021年∼2026年的預測

第4章 波特的五力分析

  • 五力的摘要
  • 買方議價能力
  • 供應商談判力
  • 新興企業的威脅
  • 替代品的威脅
  • 競爭企業的威脅
  • 市場情況

第5章 市場區隔:各產品

  • 市場區隔
  • 比較:各產品
  • Dabrafenib - 市場規模與預測:2021年∼2026年
  • Sorafenib - 市場規模與預測:2021年∼2026年
  • Vemurafenib - 市場規模與預測:2021年∼2026年
  • Encorafenib - 市場規模與預測:2021年∼2026年
  • 市場機會:各產品

第6章 客戶形勢

  • 客戶形勢概要

第7章 各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美 - 市場規模與預測:2021年∼2026年
  • 亞洲 - 市場規模與預測:2021年∼2026年
  • 歐洲 - 市場規模與預測:2021年∼2026年
  • 其他地區(ROW) - 市場規模與預測:2021年∼2026年
  • 美國 - 市場規模與預測:2021年∼2026年
  • 中國 - 市場規模與預測:2021年∼2026年
  • 印度 - 市場規模與預測:2021年∼2026年
  • 丹麥 - 市場規模與預測:2021年∼2026年
  • 加拿大 - 市場規模與預測:2021年∼2026年
  • 市場機會:各地區形勢

第8章 促進因素,課題,及趨勢

  • 推動市場要素
  • 市場課題
  • 推動因素與課題的影響
  • 市場趨勢

第9章 業者情勢

  • 概要
  • 業者情勢
  • 混亂狀況
  • 產業的風險

第10章 供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Asana BioSciences LLC
  • Bayer AG
  • BeiGene Ltd.
  • F. Hoffmann La Roche Ltd.
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Pierre Fabre SA

第11章 附錄

目錄
Product Code: IRTNTR73550

Technavio has been monitoring the braf kinase inhibitors market and it is poised to grow by $ 1.19 billion during 2022-2026, accelerating at a CAGR of 7.73% during the forecast period. Our report on the braf kinase inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the high target affinity and specificity of BRAF kinase inhibitors, the presence of a patient assistance program, and the increasing prevalence of cancer.

The braf kinase inhibitors market analysis includes product segment and geographic landscape.

Technavio's braf kinase inhibitors market is segmented as below:

By Product

  • Dabrafenib
  • Sorafenib
  • Vemurafenib
  • Encorafenib

By Geographical Landscape

  • North America
  • Asia
  • Europe
  • Rest of World (ROW)

This study identifies the expansion of research areas as one of the prime reasons driving the braf kinase inhibitors market growth during the next few years. Also, strategic alliances and growing awareness of cancer will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on braf kinase inhibitors market covers the following areas:

  • Braf kinase inhibitors market sizing
  • Braf kinase inhibitors market forecast
  • Braf kinase inhibitors market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading braf kinase inhibitors market vendors that include Asana BioSciences LLC, Bayer AG, BeiGene Ltd., F. Hoffmann La Roche Ltd., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Pierre Fabre SA. Also, the braf kinase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
  • Exhibit 06: Executive Summary - Chart on Incremental Growth
  • Exhibit 07: Executive Summary - Data Table on Incremental Growth
  • Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 09: Parent market
  • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026
  • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary
  • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
  • 4.2 Bargaining power of buyers
  • Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers
  • Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants
  • Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes
  • Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry
  • Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
  • 4.7 Market condition
  • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

  • 5.1 Market segments
  • Exhibit 24: Chart on Product - Market share 2021-2026 (%)
  • Exhibit 25: Data Table on Product - Market share 2021-2026 (%)
  • 5.2 Comparison by Product
  • Exhibit 26: Chart on Comparison by Product
  • Exhibit 27: Data Table on Comparison by Product
  • 5.3 Dabrafenib - Market size and forecast 2021-2026
  • Exhibit 28: Chart on Dabrafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibit 29: Data Table on Dabrafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibit 30: Chart on Dabrafenib - Year-over-year growth 2021-2026 (%)
  • Exhibit 31: Data Table on Dabrafenib - Year-over-year growth 2021-2026 (%)
  • 5.4 Sorafenib - Market size and forecast 2021-2026
  • Exhibit 32: Chart on Sorafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibit 33: Data Table on Sorafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibit 34: Chart on Sorafenib - Year-over-year growth 2021-2026 (%)
  • Exhibit 35: Data Table on Sorafenib - Year-over-year growth 2021-2026 (%)
  • 5.5 Vemurafenib - Market size and forecast 2021-2026
  • Exhibit 36: Chart on Vemurafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibit 37: Data Table on Vemurafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibit 38: Chart on Vemurafenib - Year-over-year growth 2021-2026 (%)
  • Exhibit 39: Data Table on Vemurafenib - Year-over-year growth 2021-2026 (%)
  • 5.6 Encorafenib - Market size and forecast 2021-2026
  • Exhibit 40: Chart on Encorafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibit 41: Data Table on Encorafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibit 42: Chart on Encorafenib - Year-over-year growth 2021-2026 (%)
  • Exhibit 43: Data Table on Encorafenib - Year-over-year growth 2021-2026 (%)
  • 5.7 Market opportunity by Product
  • Exhibit 44: Market opportunity by Product ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview
  • Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation
  • Exhibit 46: Chart on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibit 47: Data Table on Market share By Geographical Landscape 2021-2026 (%)
  • 7.2 Geographic comparison
  • Exhibit 48: Chart on Geographic comparison
  • Exhibit 49: Data Table on Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
  • Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
  • Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Asia - Market size and forecast 2021-2026
  • Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • 7.5 Europe - Market size and forecast 2021-2026
  • Exhibit 58: Chart on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 59: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 60: Chart on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibit 61: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
  • Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • 7.7 US - Market size and forecast 2021-2026
  • Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
  • Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)
  • 7.8 China - Market size and forecast 2021-2026
  • Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
  • Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
  • 7.9 India - Market size and forecast 2021-2026
  • Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ million)
  • Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ million)
  • Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%)
  • Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%)
  • 7.10 Denmark - Market size and forecast 2021-2026
  • Exhibit 78: Chart on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibit 79: Data Table on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibit 80: Chart on Denmark - Year-over-year growth 2021-2026 (%)
  • Exhibit 81: Data Table on Denmark - Year-over-year growth 2021-2026 (%)
  • 7.11 Canada - Market size and forecast 2021-2026
  • Exhibit 82: Chart on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 83: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 84: Chart on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibit 85: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity By Geographical Landscape
  • Exhibit 86: Market opportunity By Geographical Landscape ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges
  • Exhibit 87: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape
  • Exhibit 88: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption
  • Exhibit 89: Overview on factors of disruption
  • 9.4 Industry risks
  • Exhibit 90: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered
  • Exhibit 91: Vendors covered
  • 10.2 Market positioning of vendors
  • Exhibit 92: Matrix on vendor position and classification
  • 10.3 Asana BioSciences LLC
  • Exhibit 93: Asana BioSciences LLC - Overview
  • Exhibit 94: Asana BioSciences LLC - Product / Service
  • Exhibit 95: Asana BioSciences LLC - Key offerings
  • 10.4 Bayer AG
  • Exhibit 96: Bayer AG - Overview
  • Exhibit 97: Bayer AG - Business segments
  • Exhibit 98: Bayer AG - Key offerings
  • Exhibit 99: Bayer AG - Segment focus
  • 10.5 BeiGene Ltd.
  • Exhibit 100: BeiGene Ltd. - Overview
  • Exhibit 101: BeiGene Ltd. - Business segments
  • Exhibit 102: BeiGene Ltd. - Key offerings
  • Exhibit 103: BeiGene Ltd. - Segment focus
  • 10.6 F. Hoffmann La Roche Ltd.
  • Exhibit 104: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 105: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 106: F. Hoffmann La Roche Ltd. - Key news
  • Exhibit 107: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 108: F. Hoffmann La Roche Ltd. - Segment focus
  • 10.7 Novartis AG
  • Exhibit 109: Novartis AG - Overview
  • Exhibit 110: Novartis AG - Business segments
  • Exhibit 111: Novartis AG - Key offerings
  • Exhibit 112: Novartis AG - Segment focus
  • 10.8 Ono Pharmaceutical Co. Ltd.
  • Exhibit 113: Ono Pharmaceutical Co. Ltd. - Overview
  • Exhibit 114: Ono Pharmaceutical Co. Ltd. - Product / Service
  • Exhibit 115: Ono Pharmaceutical Co. Ltd. - Key offerings
  • 10.9 Pfizer Inc.
  • Exhibit 116: Pfizer Inc. - Overview
  • Exhibit 117: Pfizer Inc. - Product / Service
  • Exhibit 118: Pfizer Inc. - Key news
  • Exhibit 119: Pfizer Inc. - Key offerings
  • 10.10 Pierre Fabre SA
  • Exhibit 120: Pierre Fabre SA - Overview
  • Exhibit 121: Pierre Fabre SA - Business segments
  • Exhibit 122: Pierre Fabre SA - Key offerings
  • Exhibit 123: Pierre Fabre SA - Segment focus

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist
  • Exhibit 124: Inclusions checklist
  • Exhibit 125: Exclusions checklist
  • 11.3 Currency conversion rates for US$
  • Exhibit 126: Currency conversion rates for US$
  • 11.4 Research methodology
  • Exhibit 127: Research methodology
  • Exhibit 128: Validation techniques employed for market sizing
  • Exhibit 129: Information sources
  • 11.5 List of abbreviations
  • Exhibit 130: List of abbreviations

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Product
  • Exhibits6: Executive Summary - Chart on Incremental Growth
  • Exhibits7: Executive Summary - Data Table on Incremental Growth
  • Exhibits8: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits9: Parent market
  • Exhibits10: Market Characteristics
  • Exhibits11: Offerings of vendors included in the market definition
  • Exhibits12: Market segments
  • Exhibits13: Chart on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibits14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibits15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibits16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibits17: Five forces analysis - Comparison between 2021 and 2026
  • Exhibits18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
  • Exhibits19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
  • Exhibits20: Threat of new entrants - Impact of key factors in 2021 and 2026
  • Exhibits21: Threat of substitutes - Impact of key factors in 2021 and 2026
  • Exhibits22: Threat of rivalry - Impact of key factors in 2021 and 2026
  • Exhibits23: Chart on Market condition - Five forces 2021 and 2026
  • Exhibits24: Chart on Product - Market share 2021-2026 (%)
  • Exhibits25: Data Table on Product - Market share 2021-2026 (%)
  • Exhibits26: Chart on Comparison by Product
  • Exhibits27: Data Table on Comparison by Product
  • Exhibits28: Chart on Dabrafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibits29: Data Table on Dabrafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibits30: Chart on Dabrafenib - Year-over-year growth 2021-2026 (%)
  • Exhibits31: Data Table on Dabrafenib - Year-over-year growth 2021-2026 (%)
  • Exhibits32: Chart on Sorafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibits33: Data Table on Sorafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibits34: Chart on Sorafenib - Year-over-year growth 2021-2026 (%)
  • Exhibits35: Data Table on Sorafenib - Year-over-year growth 2021-2026 (%)
  • Exhibits36: Chart on Vemurafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibits37: Data Table on Vemurafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibits38: Chart on Vemurafenib - Year-over-year growth 2021-2026 (%)
  • Exhibits39: Data Table on Vemurafenib - Year-over-year growth 2021-2026 (%)
  • Exhibits40: Chart on Encorafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibits41: Data Table on Encorafenib - Market size and forecast 2021-2026 ($ million)
  • Exhibits42: Chart on Encorafenib - Year-over-year growth 2021-2026 (%)
  • Exhibits43: Data Table on Encorafenib - Year-over-year growth 2021-2026 (%)
  • Exhibits44: Market opportunity by Product ($ million)
  • Exhibits45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits46: Chart on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits47: Data Table on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits48: Chart on Geographic comparison
  • Exhibits49: Data Table on Geographic comparison
  • Exhibits50: Chart on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibits51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibits52: Chart on North America - Year-over-year growth 2021-2026 (%)
  • Exhibits53: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • Exhibits54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibits55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibits56: Chart on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits58: Chart on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibits59: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibits60: Chart on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits61: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibits63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibits64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibits65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibits66: Chart on US - Market size and forecast 2021-2026 ($ million)
  • Exhibits67: Data Table on US - Market size and forecast 2021-2026 ($ million)
  • Exhibits68: Chart on US - Year-over-year growth 2021-2026 (%)
  • Exhibits69: Data Table on US - Year-over-year growth 2021-2026 (%)
  • Exhibits70: Chart on China - Market size and forecast 2021-2026 ($ million)
  • Exhibits71: Data Table on China - Market size and forecast 2021-2026 ($ million)
  • Exhibits72: Chart on China - Year-over-year growth 2021-2026 (%)
  • Exhibits73: Data Table on China - Year-over-year growth 2021-2026 (%)
  • Exhibits74: Chart on India - Market size and forecast 2021-2026 ($ million)
  • Exhibits75: Data Table on India - Market size and forecast 2021-2026 ($ million)
  • Exhibits76: Chart on India - Year-over-year growth 2021-2026 (%)
  • Exhibits77: Data Table on India - Year-over-year growth 2021-2026 (%)
  • Exhibits78: Chart on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibits79: Data Table on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibits80: Chart on Denmark - Year-over-year growth 2021-2026 (%)
  • Exhibits81: Data Table on Denmark - Year-over-year growth 2021-2026 (%)
  • Exhibits82: Chart on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibits83: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibits84: Chart on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibits85: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibits86: Market opportunity By Geographical Landscape ($ million)
  • Exhibits87: Impact of drivers and challenges in 2021 and 2026
  • Exhibits88: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits89: Overview on factors of disruption
  • Exhibits90: Impact of key risks on business
  • Exhibits91: Vendors covered
  • Exhibits92: Matrix on vendor position and classification
  • Exhibits93: Asana BioSciences LLC - Overview
  • Exhibits94: Asana BioSciences LLC - Product / Service
  • Exhibits95: Asana BioSciences LLC - Key offerings
  • Exhibits96: Bayer AG - Overview
  • Exhibits97: Bayer AG - Business segments
  • Exhibits98: Bayer AG - Key offerings
  • Exhibits99: Bayer AG - Segment focus
  • Exhibits100: BeiGene Ltd. - Overview
  • Exhibits101: BeiGene Ltd. - Business segments
  • Exhibits102: BeiGene Ltd. - Key offerings
  • Exhibits103: BeiGene Ltd. - Segment focus
  • Exhibits104: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits105: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits106: F. Hoffmann La Roche Ltd. - Key news
  • Exhibits107: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits108: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits109: Novartis AG - Overview
  • Exhibits110: Novartis AG - Business segments
  • Exhibits111: Novartis AG - Key offerings
  • Exhibits112: Novartis AG - Segment focus
  • Exhibits113: Ono Pharmaceutical Co. Ltd. - Overview
  • Exhibits114: Ono Pharmaceutical Co. Ltd. - Product / Service
  • Exhibits115: Ono Pharmaceutical Co. Ltd. - Key offerings
  • Exhibits116: Pfizer Inc. - Overview
  • Exhibits117: Pfizer Inc. - Product / Service
  • Exhibits118: Pfizer Inc. - Key news
  • Exhibits119: Pfizer Inc. - Key offerings
  • Exhibits120: Pierre Fabre SA - Overview
  • Exhibits121: Pierre Fabre SA - Business segments
  • Exhibits122: Pierre Fabre SA - Key offerings
  • Exhibits123: Pierre Fabre SA - Segment focus
  • Exhibits124: Inclusions checklist
  • Exhibits125: Exclusions checklist
  • Exhibits126: Currency conversion rates for US$
  • Exhibits127: Research methodology
  • Exhibits128: Validation techniques employed for market sizing
  • Exhibits129: Information sources
  • Exhibits130: List of abbreviations